Potential Role of Estrogen Receptor Beta as a Tumor Suppressor of Epithelial Ovarian Cancer

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Bossard, Carine ^a   Busson, Muriel ^a   Vindrieux, David ^a   Gaudin, Françoise ^a   Machelon, Véronique ^a   Brigitte, Madly ^a   Jacquard, Carine ^a   Pillon, Arnaud ^b   Balaguer, Patrick ^b   Balabanian, Karl ^a   Lazennec, Gwendal ^a  

^a INSERM   (France)

^b INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A2; CYCLIN D1; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; PROTEIN KINASE B; RETINOBLASTOMA PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL LINE; CELL PROLIFERATION; CELL STRAIN BG 1; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CARCINOMA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SURVIVAL; TUMOR CELL;

CELL PROLIFERATION; ESTROGEN RECEPTOR BETA; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PHOSPHORYLATION; RETINOBLASTOMA PROTEIN; TRANSCRIPTION, GENETIC;

MUS; MUS MUSCULUS;

EID: 84866132321     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044787     Document Type: Article

References (54)

1. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC, (2001) Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 22: 255-288.
2. Cho KR, Shih Ie M, (2009) Ovarian cancer. Annu Rev Pathol 4: 287-313.
3. Rosenfeld CS, Wagner JS, Roberts RM, Lubahn DB, (2001) Intraovarian actions of oestrogen. Reproduction 122: 215-226.
4. Beral V, Bull D, Green J, Reeves G, (2007) Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 369: 1703-1710.
5. Glud E, Kjaer SK, Thomsen BL, Hogdall C, Christensen L, et al. (2004) Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. Arch Intern Med 164: 2253-2259.
6. Lacey JV Jr, Brinton LA, Leitzmann MF, Mouw T, Hollenbeck A, et al. (2006) Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort. J Natl Cancer Inst 98: 1397-1405.
7. Rossing MA, Cushing-Haugen KL, Wicklund KG, Doherty JA, Weiss NS, (2007) Menopausal hormone therapy and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 16: 2548-2556.
8. Beral V, Hannaford P, Kay C, (1988) Oral contraceptive use and malignancies of the genital tract. Results from the Royal College of General Practitioners' Oral Contraception Study. Lancet 2: 1331-1335.
9. Deligeoroglou E, Michailidis E, Creatsas G, (2003) Oral contraceptives and reproductive system cancer. Ann N Y Acad Sci 997: 199-208.
10. Katzenellenbogen BS, Katzenellenbogen JA, (2000) Estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Res 2: 335-344.
11. Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P, (2004) Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer 11: 537-551.
12. Greenlee RT, Murray T, Bolden S, Wingo PA, (2000) Cancer statistics, 2000. CA Cancer J Clin 50: 7-33.
13. Hatch KD, Beecham JB, Blessing JA, Creasman WT, (1991) Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 68: 269-271.
14. Drummond AE, Fuller PJ, (2010) The importance of ERbeta signalling in the ovary. J Endocrinol 205: 15-23.
15. Krege JH, Hodgin JB, Couse JF, Enmark E, Warner M, et al. (1998) Generation and reproductive phenotypes of mice lacking estrogen receptor beta. PNAS 95: 15677-15682.
16. Couse JF, Curtis Hewitt S, Korach KS, (2000) Receptor null mice reveal contrasting roles for estrogen receptor alpha and beta in reproductive tissues. J Steroid Biochem Mol Biol 74: 287-296.
17. Couse JF, Yates MM, Deroo BJ, Korach KS, (2005) Estrogen Receptor-{beta} Is Critical to Granulosa Cell Differentiation and the Ovulatory Response to Gonadotropins. Endocrinology 146: 3247-3262.
18. Emmen JM, Couse JF, Elmore SA, Yates MM, Kissling GE, et al. (2005) In vitro growth and ovulation of follicles from ovaries of estrogen receptor (ER){alpha} and ER{beta} null mice indicate a role for ER{beta} in follicular maturation. Endocrinology 146: 2817-2826.
19. Pujol P, Rey JM, Nirde P, Roger P, Gastaldi M, et al. (1998) Differential expression of estrogen receptor-alpha and-beta messenger RNAs as a potential marker of ovarian carcinogenesis. Cancer Res 58: 5367-5373.
20. Rutherford T, Brown WD, Sapi E, Aschkenazi S, Munoz A, et al. (2000) Absence of estrogen receptor-beta expression in metastatic ovarian cancer. Obstet Gynecol 96: 417-421.
21. Lazennec G, (2006) Estrogen receptor beta, a possible tumor suppressor involved in ovarian carcinogenesis. Cancer Lett 231: 151-157.
22. Chan KK, Wei N, Liu SS, Xiao-Yun L, Cheung AN, et al. (2008) Estrogen receptor subtypes in ovarian cancer: a clinical correlation. Obstet Gynecol 111: 144-151.
23. Halon A, Nowak-Markwitz E, Maciejczyk A, Pudelko M, Gansukh T, et al. (2011) Loss of estrogen receptor beta expression correlates with shorter overall survival and lack of clinical response to chemotherapy in ovarian cancer patients. Anticancer Res 31: 711-718.
24. Burges A, Bruning A, Dannenmann C, Blankenstein T, Jeschke U, et al. (2010) Prognostic significance of estrogen receptor alpha and beta expression in human serous carcinomas of the ovary. Arch Gynecol Obstet 281: 511-517.
25. Lurie G, Wilkens LR, Thompson PJ, Shvetsov YB, Matsuno RK, et al. (2011) Estrogen Receptor Beta rs1271572 Polymorphism and Invasive Ovarian Carcinoma Risk: Pooled Analysis within the Ovarian Cancer Association Consortium. PLoS One 6: e20703.
26. De Stefano I, Zannoni GF, Prisco MG, Fagotti A, Tortorella L, et al. (2011) Cytoplasmic expression of estrogen receptor beta (ERbeta) predicts poor clinical outcome in advanced serous ovarian cancer. Gynecol Oncol 122: 573-579.
27. Geisinger KR, Kute TE, Pettenati MJ, Welander CE, Dennard Y, et al. (1989) Characterization of a human ovarian carcinoma cell line with estrogen and progesterone receptors. Cancer 63: 280-288.
28. Baldwin WS, Curtis SW, Cauthen CA, Risinger JI, Korach KS, et al. (1998) Bg-1 ovarian cell line - an alternative model for examining estrogen-dependent growth in vitro. In Vitro Cellular & Developmental Biology Animal 34: 649-654.
29. Shaw TJ, Senterman MK, Dawson K, Crane CA, Vanderhyden BC, (2004) Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol Ther 10: 1032-1042.
30. Cheng J, Lee EJ, Madison LD, Lazennec G, (2004) Expression of estrogen receptor beta in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis. FEBS Lett 566: 169-172.
31. Lazennec G, Bresson D, Lucas A, Chauveau C, Vignon F, (2001) ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology 142: 4120-4130.
32. Picard N, Charbonneau C, Sanchez M, Licznar A, Busson M, et al. (2008) Phosphorylation of Activation Function-1 Regulates Proteasome-Dependent Nuclear Mobility and E6-Associated Protein Ubiquitin Ligase Recruitment to the Estrogen Receptor {beta}. Mol Endocrinol 22: 317-330.
33. Langdon SP, Lawrie SS, Hay FG, Hawkes MM, McDonald A, et al. (1988) Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res 48: 6166-6172.
34. Freund A, Chauveau C, Brouillet JP, Lucas A, Lacroix M, et al. (2003) IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells. Oncogene 22: 256-265.
35. Foster JS, Henley DC, Ahamed S, Wimalasena J, (2001) Estrogens and cell-cycle regulation in breast cancer. Trends Endocrinol Metab 12: 320-327.
36. Treeck O, Pfeiler G, Mitter D, Lattrich C, Piendl G, et al. (2007) Estrogen receptor {beta}1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells. J Endocrinol 193: 421-433.
37. Licznar A, Caporali S, Lucas A, Weisz A, Vignon F, et al. (2003) Identification of genes involved in growth inhibition of breast cancer cells transduced with estrogen receptor. FEBS Lett 553: 445-450.
38. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, et al. (2004) Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 64: 423-428.
39. Johnson DG, Walker CL, (1999) Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol 39: 295-312.
40. Burgering BM, Medema RH, (2003) Decisions on life and death: FOXO Forkhead transcription factors are in command when PKB/Akt is off duty. J Leukoc Biol 73: 689-701.
41. Alarid ET, Bakopoulos N, Solodin N, (1999) Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation. Mol Endocrinol 13: 1522-1534.
42. Lonard DM, Nawaz Z, Smith CL, O'Malley BW, (2000) The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation. Mol Cell 5: 939-948.
43. Reid G, Hubner MR, Metivier R, Brand H, Denger S, et al. (2003) Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol Cell 11: 695-707.
44. Matthews J, Wihlen B, Tujague M, Wan J, Strom A, et al. (2006) Estrogen receptor (ER) beta modulates ERalpha-mediated transcriptional activation by altering the recruitment of c-Fos and c-Jun to estrogen-responsive promoters. Mol Endocrinol 20: 534-543.
45. Pettersson K, Grandien K, Kuiper GG, Gustafsson JA, (1997) Mouse estrogen receptor beta forms estrogen response element-binding heterodimers with estrogen receptor alpha. Mol Endocrinol 11: 1486-1496.
46. Cowley SM, Hoare S, Mosselman S, Parker MG, (1997) Estrogen receptors alpha and beta form heterodimers on DNA. J Biol Chem 272: 19858-19862.
47. Williams C, Edvardsson K, Lewandowski SA, Strom A, Gustafsson JA, (2008) A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells. Oncogene 27: 1019-1032.
48. Lindberg MK, Moverare S, Skrtic S, Gao H, Dahlman-Wright K, et al. (2003) Estrogen Receptor (ER)-{beta} Reduces ER{alpha}-Regulated Gene Transcription, Supporting a "Ying Yang" Relationship between ER{alpha} and ER{beta} in Mice. Mol Endocrinol 17: 203-208.
49. Duong V, Licznar A, Margueron R, Boulle N, Busson M, et al. (2006) ERalpha and ERbeta expression and transcriptional activity are differentially regulated by HDAC inhibitors. Oncogene 25: 1799-1806.
50. Yap OW, Bhat G, Liu L, Tollefsbol TO, (2009) Epigenetic modifications of the Estrogen receptor beta gene in epithelial ovarian cancer cells. Anticancer Res 29: 139-144.
51. Suzuki F, Akahira J, Miura I, Suzuki T, Ito K, et al. (2008) Loss of estrogen receptor beta isoform expression and its correlation with aberrant DNA methylation of the 5'-untranslated region in human epithelial ovarian carcinoma. Cancer Sci 99: 2365-2372.
52. Moll F, Katsaros D, Lazennec G, Hellio N, Roger P, et al. (2002) Estrogen induction and overexpression of fibulin-1C mRNA in ovarian cancer cells. Oncogene 21: 1097-1107.
53. Lucas A, Kremer EJ, Hemmi S, Luis J, Vignon F, et al. (2003) Comparative transductions of breast cancer cells by three DNA viruses. Biochem Biophys Res Commun 309: 1011-1016.
54. Pillon A, Servant N, Vignon F, Balaguer P, Nicolas JC, (2005) In vivo bioluminescence imaging to evaluate estrogenic activities of endocrine disrupters. Anal Biochem 340: 295-302.